Andrea Rubbert-Roth
Rheumatologie · Dept. I
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents
Rubbert-Roth A, Szabó M, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 2019; 18:102398.
19.10.2019Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents
19.10.2019Autoimmun Rev 2019; 18:102398
Rubbert-Roth Andrea, Szabó Melinda Zsuzsanna, Kedves Melinda, Nagy György, Atzeni Fabiola, Sarzi-Puttini Piercarlo
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open 2019; 5:e001017.
18.10.2019Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
18.10.2019RMD Open 2019; 5:e001017
Burmester Gerd R, Boklage Susan, St John Gregory, Thangavelu Karthinathan, Gervitz Leon, Pena-Rossi Claudia, Gómez-Centeno Antonio, Raskina Tatiana, Amital Howard, Rubbert-Roth Andrea, Strand Vibeke, Genovese Mark C
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med 2019; 8
26.09.2019Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
26.09.2019J Clin Med 2019; 8
Mueller Ruediger B, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Hasler Paul, Souza Alexander, Durmisi Mirsada, Mattow Frederik, Popp Florian, Hasler Caroline, von Kempis Johannes
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin Exp Rheumatol 2019; 37:937-945.
16.04.2019Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
16.04.2019Clin Exp Rheumatol 2019; 37:937-945
Dörner Thomas, Peters Marvin A, Schwenke Holger, Rubbert-Roth Andrea, Krüger Klaus, Kurthen Reiner, Kellner Herbert, Kästner Peter, Engel Andreas, Schmalzing Marc, Iking-Konert Christof, Burmester Gerd-Rüdiger, Schulze-Koops Hendrik, Tony Hans-Peter
[Pulmonary involvement in rheumatoid arthritis]
Krause A, Rubbert-Roth A. [Pulmonary involvement in rheumatoid arthritis]. Z Rheumatol 2019; 78:228-235.
01.04.2019[Pulmonary involvement in rheumatoid arthritis]
01.04.2019Z Rheumatol 2019; 78:228-235
Krause A, Rubbert-Roth Andrea
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]
Fiehn C, Kuipers J, Lorenz H, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony H, Wassenberg S, Wollenhaupt J, Krause A, Kellner H, Gromnica-Ihle E, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Krüger K. [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. Z Rheumatol 2018; 77:35-53.
01.08.2018[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]
01.08.2018Z Rheumatol 2018; 77:35-53
Fiehn C, Kuipers J, Lorenz H-M, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth Andrea, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony H-P, Wassenberg S, Wollenhaupt J, Krause A, Kellner H, Gromnica-Ihle E, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Krüger K
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513-2524.
18.06.2018Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
18.06.2018Lancet 2018; 391:2513-2524
Genovese Mark C, Meerwein Sebastian, Mohamed Mohamed-Eslam F, Zhou Yijie, Zhang Ying, Rubbert-Roth Andrea, Hall Stephen, Combe Bernard, Fleischmann Roy, Pangan Aileen L
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rubbert-Roth A, Furst D, Nebesky J, Jin A, Berber E. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatol Ther 2018; 5:21-42.
03.03.2018A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
03.03.2018Rheumatol Ther 2018; 5:21-42
Rubbert-Roth Andrea, Furst Daniel E, Nebesky Jan Michael, Jin Angela, Berber Erhan
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll R, Elbez Y, Rauch C. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Arthritis Res Ther 2018; 20:1.
02.01.2018Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
02.01.2018Arthritis Res Ther 2018; 20:1
Alten Rieke, Burkhardt Harald, Feist Eugen, Krüger Klaus, Rech Juergen, Rubbert-Roth Andrea, Voll Reinhard E, Elbez Yedid, Rauch Christiane
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?
Rubbert-Roth A, Atzeni F, Masala I, Caporali R, Montecucco C, Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. Autoimmun Rev 2018; 17:24-28.
01.01.2018TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?
01.01.2018Autoimmun Rev 2018; 17:24-28
Rubbert-Roth Andrea, Atzeni F, Masala IF, Caporali R, Montecucco C, Sarzi-Puttini P
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?
Rubbert-Roth A, Atzeni F, Masala I, Caporali R, Montecucco C, Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. Autoimmun Rev 2017; 17:24-28.
03.11.2017TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?
03.11.2017Autoimmun Rev 2017; 17:24-28
Rubbert-Roth Andrea, Atzeni Fabiola, Masala Ignazio Francesco, Caporali Roberto, Montecucco Carlomaurizio, Sarzi-Puttini Piercarlo
[51-year-old man with with acute coronary syndrome and bipulmonary infiltrates]
Michels G, Radtke A, Rubbert-Roth A, Pfister R, Quaas A. [51-year-old man with with acute coronary syndrome and bipulmonary infiltrates]. Dtsch Med Wochenschr 2017; 142:1545.
10.10.2017[51-year-old man with with acute coronary syndrome and bipulmonary infiltrates]
10.10.2017Dtsch Med Wochenschr 2017; 142:1545
Michels Guido, Radtke Anne, Rubbert-Roth Andrea, Pfister Roman, Quaas Alexander
A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement
Rubbert-Roth A, Jacobs J, Bijlsma J, Welsing P. A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement. Ann Rheum Dis 2017; 77:1085-1086.
23.06.2017A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement
23.06.2017Ann Rheum Dis 2017; 77:1085-1086
Rubbert-Roth Andrea, Jacobs Johannes W G, Bijlsma Johannes W J, Welsing Paco M J